NEW DATA from the first prospective, randomized, large-scale trial of prostate cancer ever reported indicate screening in the general population may significantly decrease prostate cancer deaths.
"PSA testing saves lives," declared Fernand Labrie, MD, PhD, lead investigator of the Quebec Prospective and Randomized Study, and director of research at Laval University, Quebec. The 8-year study, begun in 1988, randomly divided 46193 men, ranging in age from 45 to 80 years, between screening and no screening. "There was a 69% decrease in deaths from prostate cancer in the group of men who were screened and treated early for prostate cancer at the time of diagnosis," said Labrie.
Pat Phillips. Mixed Response to New PSA Screening Study. JAMA. 1998;280(1):8–9. doi:10.1001/jama.280.1.8-JMN0701-2-1